Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma	Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-03-25		NCT04756726

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
C4 Therapeutics, Inc.	3

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Colorado Blood Cancer Institute (Sarah Cannon Research Institute)	Denver	United States	1
Dana-Farber Cancer Institute	Boston	United States	626
Emory University Hospital	Atlanta	United States	131
Massachusetts General Hospital	Boston	United States	1015
Mayo Clinic	Rochester	United States	664
Mayo Clinic	Phoenix	United States	50
Mayo Clinic	Jacksonville	United States	122
Medical College of Wisconsin	Milwaukee	United States	483
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Mt Sinai Medical Center	New York	United States	1
Tennessee Oncology (Sarah Cannon Research Institute)	Nashville	United States	1
University of California-San Francisco	San Francisco	United States	5
Washington University School of St. Louis	St Louis	United States	1